相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease
Susanna Waters et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia
Per Svenningsson et al.
MOVEMENT DISORDERS (2020)
Pharmacology and Therapeutic Potential of the 5-HT7 Receptor
Kevin M. Blattner et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Differential α2A- and α2C-adrenoceptor protein expression in presynaptic and postsynaptic density fractions of postmortem human prefrontal cortex
Amaia M. Erdozain et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
The Role of Dopamine D3 Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens
Mei Huang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update
Daniela Cadinu et al.
NEUROPHARMACOLOGY (2018)
Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity
Jan Kehr et al.
PSYCHOPHARMACOLOGY (2018)
Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission
Alan L. Pehrson et al.
FRONTIERS IN PHARMACOLOGY (2018)
Postural Dynamics Are Associated With Cognitive Decline in Parkinson's Disease
Annette Pantall et al.
FRONTIERS IN NEUROLOGY (2018)
Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: A preliminary investigation
Samantha L. McLean et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Fluparoxan: A Comprehensive Review of its Discovery, Adrenergic and CNS Activity and Treatment of Cognitive Dysfunction in Central Neurodegenerative Diseases
Alan D. Borthwick
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2017)
Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective
Madeleine Monique Uys et al.
FRONTIERS IN PSYCHIATRY (2017)
In Vivo Systems Response Profiling and Multivariate Classification of CNS Active Compounds: A Structured Tool for CNS Drug Discovery
Susanna Waters et al.
ACS CHEMICAL NEUROSCIENCE (2017)
The α2C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat
Madeleine M. Uys et al.
BEHAVIOURAL PHARMACOLOGY (2017)
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia
Jennifer Y. Y. Szeto et al.
CURRENT NEUROPHARMACOLOGY (2016)
Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology
Jo C. Neill et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders
Mark J. Millan et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Early Synaptic Dysfunction in Parkinson's Disease: Insights From Animal Models
Tommaso Schirinzi et al.
MOVEMENT DISORDERS (2016)
Non motor subtypes and Parkinson's disease
Anna Sauerbier et al.
PARKINSONISM & RELATED DISORDERS (2016)
Npas4: Linking Neuronal Activity to Memory
Xiaochen Sun et al.
TRENDS IN NEUROSCIENCES (2016)
Parkinson's disease dementia: a neural networks perspective
James Gratwicke et al.
BRAIN (2015)
Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date
Agnieszka Nikiforuk
CNS DRUGS (2015)
Role of sigma-1 receptors in neurodegenerative diseases
Linda Nguyen et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2015)
The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system
K. Ray Chaudhuri et al.
PARKINSONISM & RELATED DISORDERS (2015)
Treatment of Psychosis and Dementia in Parkinson's Disease
Jennifer G. Goldman et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2014)
Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism
Kristian Gaarn du Jardin et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats
Ashley Wallace et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats
Helen L. Rowley et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Cognitive deficits in Parkinson's disease: A cognitive neuroscience perspective
Trevor W. Robbins et al.
MOVEMENT DISORDERS (2014)
Survival in Parkinson's disease. Relation with motor and non-motor features
Lonneke M. L. de Lau et al.
PARKINSONISM & RELATED DISORDERS (2014)
Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study
Alan L. Pehrson et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
Polypharmacology - Foe or Friend?
Jens-Uwe Peters
JOURNAL OF MEDICINAL CHEMISTRY (2013)
The current and projected economic burden of Parkinson's disease in the United States
Stacey L. Kowal et al.
MOVEMENT DISORDERS (2013)
Corticostriatal connectivity and its role in disease
Gordon M. G. Shepherd
NATURE REVIEWS NEUROSCIENCE (2013)
Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats
Arne Mork et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2013)
Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease
Nandakumar S. Narayanan et al.
REVIEWS IN THE NEUROSCIENCES (2013)
The enemy within: propagation of aberrant corticostriatal learning to cortical function in Parkinson's disease
Jeff A. Beeler et al.
FRONTIERS IN NEUROLOGY (2013)
Predictors of Survival in Patients With Parkinson Disease
Allison W. Willis et al.
ARCHIVES OF NEUROLOGY (2012)
Cognitive Impairment in Parkinson Disease: Impact on Quality of Life, Disability, and Caregiver Burden
Iracema Leroi et al.
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2012)
Concomitant Release of Ventral Tegmental Acetylcholine and Accumbal Dopamine by Ghrelin in Rats
Elisabet Jerlhag et al.
PLOS ONE (2012)
Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks
Amy F. T. Arnsten
BIOLOGICAL PSYCHIATRY (2011)
Why so Few Drug Targets: A Mathematical Explanation?
Kyaw Tun et al.
CURRENT COMPUTER-AIDED DRUG DESIGN (2011)
The Economic Impact of Cognitive Impairment in Parkinson's Disease
Corinna Vossius et al.
MOVEMENT DISORDERS (2011)
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease
Klaus Seppi et al.
MOVEMENT DISORDERS (2011)
Parkinson's Disease: The Quintessential Neuropsychiatric Disorder
Daniel Weintraub et al.
MOVEMENT DISORDERS (2011)
Regulation and function of immediate-early genes in the brain: Beyond neuronal activity markers
Hiroyuki Okuno
NEUROSCIENCE RESEARCH (2011)
Atomoxetine facilitates attentional set shifting in adolescent rats
Rachel E. Cain et al.
DEVELOPMENTAL COGNITIVE NEUROSCIENCE (2011)
National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry
Ramin Mojtabai et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
In vivo pharmacology of the dopaminergic stabilizer pridopidine
Henrik Ponten et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Attenuation of Phencyclidine-Induced Object Recognition Deficits by the Combination of Atypical Antipsychotic Drugs and Pimavanserin (ACP 103), a 5-Hydroxytryptamine2A Receptor Inverse Agonist
S. Snigdha et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism
Joanna C. Neill et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Beneficial effects of desipramine on cognitive function of chronically stressed rats are mediated by α1-adrenergic receptors in medial prefrontal cortex
Corina O. Bondi et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
The Arc of synaptic memory
Clive R. Bramham et al.
EXPERIMENTAL BRAIN RESEARCH (2010)
The Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation
T.W. Robbins et al.
Annual Review of Neuroscience (2009)
Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediate-early gene Arc in the juvenile and adult brain
Partha S. Banerjee et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2009)
D1-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia
Samantha L. McLean et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus
Yvette A. M. Grimbergen et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2009)
Cognitive impairment in incident, untreated Parkinson disease The Norwegian ParkWest Study
D. Aarsland et al.
NEUROLOGY (2009)
Effect of acute and repeated treatment with desipramine or methylphenidate on serial reversal learning in rats
Emanuele Seu et al.
NEUROPHARMACOLOGY (2009)
Poor attentional function predicts cognitive decline in patients with non-demented Parkinson's disease independent of motor phenotype
J-P Taylor et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Differential expression of IEG mRNA in rat brain following acute treatment with clozapine or haloperidol: a semi-quantitative RT-PCR study
M. J. Robbins et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Mariese A. Hely et al.
MOVEMENT DISORDERS (2008)
Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat
B. Grayson et al.
BEHAVIOURAL BRAIN RESEARCH (2007)
Influence of gender on working and spatial memory in the novel object recognition task in the rat
J. S. Sutcliffe et al.
BEHAVIOURAL BRAIN RESEARCH (2007)
Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function
Craig W. Berridge et al.
BIOLOGICAL PSYCHIATRY (2006)
The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm
Z Abdul-Monim et al.
BEHAVIOURAL BRAIN RESEARCH (2006)
Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat
Chad J. Swanson et al.
NEUROPHARMACOLOGY (2006)
Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine
ET Tzavara et al.
MOLECULAR PSYCHIATRY (2006)
Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability
MDS Lapiz et al.
NEUROSCIENCE (2006)
Dementia in Parkinson disease - Functional imaging of cholinergic and dopaminergic pathways
R Hilker et al.
NEUROLOGY (2005)
The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration:: Comparison with a selective 5-HT2C receptor antagonist
CS Shilliam et al.
NEUROPSYCHOPHARMACOLOGY (2005)
Alpha-adrenergic receptor (α2A) is colocalized in basal forebrain cholinergic neurons:: A light and electron microscopic double immunolabeling study
L Zaborszky et al.
JOURNAL OF NEUROCYTOLOGY (2004)
Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease - An in vivo positron emission tomographic study
NI Bohnen et al.
ARCHIVES OF NEUROLOGY (2003)
Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic
P Devoto et al.
PSYCHOPHARMACOLOGY (2003)
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in Attention Deficit/Hyperactivity Disorder
FP Bymaster et al.
NEUROPSYCHOPHARMACOLOGY (2002)
Acute handling stress modulates methylphenidate-induced catecholamine overflow in the medial prefrontal cortex
DA Marsteller et al.
NEUROPSYCHOPHARMACOLOGY (2002)
Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat
S Shirazi-Southall et al.
NEUROPSYCHOPHARMACOLOGY (2002)
Phencyclidine supersensitivity in rats with neonatal dopamine loss
SS Moy et al.
PSYCHOPHARMACOLOGY (2002)
Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum
J Ichikawa et al.
NEUROPSYCHOPHARMACOLOGY (2002)
Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum
BHC Westerink et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
分享论文
